Patients with a history of, or current grade depression are not eligible Prior or current invasive malignancy with current evidence of active disease within the past years Inclusion Criteria:\n\n Patients aged to < years with at least one non severe comorbidity ie disease or\n syndrome with mild to moderate clinical or diagnostic observations or lab abnormalities\n which could increase the risk of toxicity and/or early death of intensive chemotherapy in\n the opinion of the investigator and are not contra-indicated for non-intensive\n chemotherapy.\n\n or ? years with or without any comorbidity at the time of the informed consent\n signature;\n\n Newly diagnosed, untreated de novo or secondary AML according to WHO classification;\n\n Exclusion Criteria:\n\n - Prior or current treatment with chemotherapy for any myeloid disorder (excluding\n hydroxyurea) or radiotherapy for extramedullary involvement within weeks of\n randomization;\n\n - Prior treatment with decitabine, azacitidine, or cytarabine;\n\n - Prior malignancies for years with exception of basal cell, squamous cell carcinoma\n of the skin, or carcinoma \ in situ \ of the cervix or breast;\n\n - Chronic myelogenous or acute promyelocytic leukaemia;\n\n - Known CNS involvement;\n\n - Patient eligible to bone marrow or stem cell transplant;\n\n - WBC ? ./mm;\n\n - Impaired renal function with Creatinine clearance < mL/min/.m according to the\n MDRD formula;\n\n - Serum bilirubin ? . x ULN and/or AST and/or ALT ? . x ULN (upper limit of normal\n value);\n\n - Calcemia ? . mmol/L ( mg/L) at screening assessment (corrected with\n albuminemia);\n\n - History of diseases known to be associated with calcium disorders: ongoing\n hyperparathyroidism, sarcoidosis.;\n\n - Presence or history of symptomatic kidney stones in the last years;\n\n - Hypersensitivity to any of the excipients of decitabine (Potassium dihydrogen\n phosphate (E) ; Sodium hydroxide (E) ; Hydrochloric acid (for pH adjustment) or\n to the excipient of inecalcitol tablets (lactose);\n\n - Current use of drugs known to influence serum calcium (such as thiazide diuretics,\n teriparatide, calcitonin and multivitamin supplements containing > IU of vitamin D\n or calcium);\n\n - Current use of digitalis;\n\n - Current use of drugs which could influence bioavailability of inecalcitol (such as\n magnesium-containing antacids, bile-resin binders);\n\n - Use of any other experimental drug or therapy or vitamin D supplementation within \n weeks of randomization;\n\n - Known HIV;\n\n - Patients who are eligible for intensive induction therapy with curative intent;\n\n - Refractory congestive heart failure;\n\n - Active infection resistant to anti-infective therapy;\n\n - Documented pulmonary disease with DLCO ? % or FEV? %, or dyspnea at rest or\n requiring oxygen, or any pleural neoplasm or uncontrolled lung neoplasm;\n\n - Liver cirrhosis Child B or C or acute viral hepatitis;\n\n - Current mental illness requiring psychiatric hospitalization, institutionalization or\n intensive outpatient management, or current cognitive status that produces dependence\n (as confirmed by the specialist) not controlled by the caregiver;\n\n - Uncontrolled neoplasia; Current enrollment in any other investigational treatment study Current treatment with oral or parenteral anti-coagulants/antiplatelet agents Subjects with active HSV- infection on current valacyclovir, acyclovir or ganciclovir therapy must be off treatment with any of these agents at least days prior to surgery history of or current cardiac issues Patients with uncontrolled inter-current illness are excluded Current active treatment in another clinical study. History or current diagnosis of Pulmonary Alveolar Proteinosis or Hypoxemia Current or anti-cancer therapy w/in wks pre-study or w/Grade ? side effects not resolved w/in wks pre-study Uncontrolled inter-current illness Presence of another malignancy requiring current treatment that would preclude the use of all of the study treatments or the ability to monitor the natural history of MCD untreated Current symptom of keratitis or retinopathy at >= grade Current use of tobacco product other than cigarettes (e.g. e-cigarettes, smokeless tobacco) Current use of non-nucleoside reverse transcriptase inhibitors (NNRTI) including efavirenz, rilpivirine, etravirine, delavirdine, nevirapine, and lersivirine Current use of statins or fibrates for any time during the months prior to the study Participants may not have current or history of clinically significant muscle disorders (eg, myositis), recent unresolved muscle injury, or any condition known to elevate serum CK levels Known current or a history of hepatitis B or C virus, including chronic and dormant states, unless disease has been treated and confirmed cleared History and/or current evidence of endocrine alteration of calcium-phosphate homeostasis Presence of current angina; Undergoing or have plans to undergo changes to current cancer treatment. Current diagnosis of symptomatic bradycardia Known current or a history of hepatitis B or C virus, including chronic and dormant states, unless disease has been treated and confirmed cleared Serious inter-current medical illness which would interfere with the ability of the patient to carry out the treatment program Current use of warfarin for any reason; NOTE: if patient can be safely transitioned to another anticoagulant, they may be eligible provided other criteria are satisfied Patients must not have current evidence of another malignancy that requires treatment Current active treatment in another clinical study Current use or anticipated need for alternative, holistic, naturopathic, or botanical formulations used for the purpose of cancer treatment No uncontrolled, inter-current or recent illness that in the investigators opinion precludes participation in the study, including those undergoing therapy for a separate invasive malignancy Subjects with bleeding diatheses, thrombocytopenia or current anticoagulant use Subjects in the combination therapy arms must be eligible to receive erlotinib, or nivolumab per most current prescribing information, or at the discretion of the Investigator. More than prior relapses (not counting the current relapse being treated on this study) Current histologically transformed disease. Current infection Current anticoagulant therapy; (acetylsalicylic acid [ASA] =< mg per day is allowed) Other malignancy that would interfere with the current intervention NSCLC cohort only: current smoker Current use of antibiotic rinses or troches Current progestin-based hormone replacement therapy. Current or prior radiation to the left hemithorax Patients who are on current long term treatment (? consecutive weeks) with Aspirin, NSAID or Cox- inhibitors Patient on active current treatment of antiplatelet agents (i.e. off-study Aspirin, clopidogrel, ticlopidine) Current major depression. Current treatment in another clinical study Note: Current or recent use of intra-articular, topical or inhaled glucocorticoid therapy is acceptable; History of or current immunodeficiency disease or prior treatment compromising immune function Current use of exogenous testosterone Current use of tamoxifen, aromatase inhibitors, or SERMs for a breast cancer indication for at last six months History or current evidence of hyperthyroidism that would increase metabolism of itraconazole Known past or current malignancy other than inclusion diagnosis, except for: Patients with current use of megestrol acetate (use within days of day ) will be excluded No current or active dermatologic diagnoses that would preclude interpretation of skin toxicities of BKM and BYL Current or prior HTLV- associated inflammatory diseases, including but not limited to myelopathy, uveitis, arthropathy, pneumonitis, or a Sjogrens disease-like disorder Any current -alpha reductase inhibitors (history of use >= months prior to MRI is acceptable) Serious inter-current medical illness which would interfere with the ability of the patient to carry out the treatment program Patients who are not a candidate for an unrelated donor allogeneic HSCT based on the current institutional BMT program clinical practice guidelines; organ function criteria will be utilized per the current institutional BMT program clinical practice guidelines; there will be no restriction to study entry based on hematological parameters Any patients with a history of tamoxifen or raloxifene use within two years of current DCIS diagnosis are not eligible Current or history of clinically significant muscle disorders (e.g., myositis), recent unresolved muscle injury, or any condition known to elevate serum CK levels Subjects with uncontrolled and significant inter-current illness. Is a current smoker Patients with history and/or current evidence of endocrine alteration of calcium-phosphate homeostasis History or current evidence of current or prior IV drug users, current or prior IV drug users, Known past or current malignancy other than inclusion diagnosis, except for: Uncontrolled inter-current illness, per protocol. History of or current clinical, radiographic, or pathologic evidence of in-transit metastases, satellite, or microsatellite lesions Current use of or =< weeks prior to registration of anti-androgens such as flutamide, estrogens, ketoconazole, finasteride, or megestrol acetate Agree to allow the sponsor to collect data on all GBM-related treatments received after the patient comes off the current study, and to collect survival data after the patient comes off the current study. Current history of neoplasm other than the entry diagnosis. Exceptions are: Subjects who have a history or current evidence of malignant biliary obstruction requiring biliary stent. Current use of exogenous hormones Current use of clobetasol propionate Current indwelling urinary stent Prior or current treatment with a cMet inhibitor Uncontrolled inter-current illness, per protocol Subjects with a past or current diagnosis of another malignancy that will interfere with conduct of the trial; patients with past or current cancer diagnoses other than ACC are allowed to enroll if the investigator believes it will not interfere with trial conduct No prior therapy with the exception of cycle of chemotherapy based on current diagnosis and clinical condition sexual abstinence (only if this is in line with the patient's current lifestyle) Previous or current history of a myeloproliferative disease Current use of megestrol acetate (Use within days of Day ) Large cell transformation. However, subjects with a history of LCT but without current aggressive disease and no current evidence of LCT on pathology in skin and lymph nodes would be eligible. Current treatment with nitrates Are unable to discontinue current treatment for CTCL due to risk of progression Current spontaneous urinary incontinence. Current use of a prohibitive medication(s) Current Spigelman Stage or . (Refer to Appendix A for Modified Spigelman Score and Classification table). A history of AEs with prior interleukin (IL)- or Interferon will not preclude subjects from entering the current study Current enrollment in any other investigational treatment study Prior therapy for advanced malignancy with no current curative option Patients with previous history or current presence of neurological disorders (with the exception of myasthenia gravis), including epilepsy (although controlled by anticonvulsant therapy), Parkinson's disease and extra-pyramidal syndromes. Current uncontrolled hyperthyroidism Patients with previous history or current presence of neurological disorders, including epilepsy (although controlled by anticonvulsant therapy), Parkinson's disease and extra-pyramidal syndromes Current carcinoma of the breast current symptomatic radiation proctitis requiring creams; certain heart problems, active or chronic infections, serious significant diseases, AIHA requiring treatment, other current cancer or within last years Duration and extent of current episode of AA Current use of FWGE Current use (within days of day ) of megestrol acetate. Current anticoagulant therapy (acetylsalicylic acid [ASA] =< mg per day allowed) Another current or previous malignancy within years of study entry unless approved by the sponsor Current or previous other malignancy within years of study entry without sponsor approval Current use of drugs with known cardiotoxicity Thrombectomy, insertion of a caval filter, or use of a fibrinolytic agent to treat the current (index) episode of DVT and/or PE; Treatment with therapeutic doses of an anticoagulant other than that used for pretreatment of the current (index) VTE episode prior to randomization; Any other current malignancy Known current or a history of hepatitis B or C virus, including chronic and dormant states, unless disease has been treated and confirmed cleared Known past or current malignancy other than inclusion diagnosis, except for: Current (within last month) use of chemotherapy for breast or other malignancy Current (within last months) use of radiation for breast or other malignancy Recent (within last month) or current intensive manual lymphatic drainage (MLD) and/or short stretch bandage use Any other current malignancy Current enrollment in another clinical study. Current use of any platelet functioning inhibitors (including aspirin) within days of first on-study thrombokinetic study Any prior or current malignancy or myeloproliferative or immunodeficiency disorder. Any prior or current malignancy or myeloproliferative disorder. Current or recent (within -months) use of lipid-lowering medication Other current malignancy than the disease under study Current diagnosis of primary cutaneous ALCL (those with systemic ALCL are eligible) History or current evidence of hyperthyroidism that would increase metabolism of Itraconazole Current or recent pregnancy (within months), Current diagnosis for depression, including treatment with an SSRI. Known or suspected current diagnosis of non GCTB giant cell-rich tumors Known or suspected current diagnosis of brown cell tumor of bone or Paget's disease Any current renal replacement therapy Untreated current severe depression; currently treated depression is permitted if treatment is stable Current psychotherapy (regular appointment[s] with a psychologist, counselor, or therapist within the last days) History of current oropharyngeal dysphagia unrelated to cancer diagnosis (e.g. dysphagia due to underlying neurogenic disorder) Recent or current participation in educational/behavioral intervention study with similar focus Active and current use of illegal recreational drugs Current venous thrombosis in either upper extremity or be on current anticoagulant therapy Current (weekly) use of cannabis Previous or current neurologic disease affecting the lower hemithorax or below Patient is being treated with oxymetazoline for allergic rhinitis or has a disorder or current medication use likely to adversely affect normal functioning of the nasal mucosa Subjects with a current or past history of schizophrenia will also be excluded Consistent with previous chemoprevention adherence research, patients will be excluded due to the presence of the following psychiatric conditions:\r\n* A lifetime history of dementia (ICD codes F-, F-, F-, F-);\r\n* A lifetime history of a psychotic disorder (ICD codes: F-F-);\r\n* A current diagnosis of a manic episode (ICD codes F-);\r\n* Current uncontrolled major depressive disorder (ICD codes F-);\r\n* A current diagnosis of any mental and behavioral disorders due to psychoactive substance use (excluding nicotine-related diagnoses) (ICD codes: F- F-, except for nicotine-related diagnoses); and,\r\n* Current intoxication Current treatment with pregabalin Current evidence of cardiac arrhythmias defined as corrected QD interval (QTc) >= mm/sec Current vaginal infection Failed to receive satisfactory improvement from one prior antidepressant medication at or above the minimal effective dose and duration in the current depressive episode Current use of insulin or sulfonylureads for glycemic control, or history of ketoacidosis Current smoker of >= cigarettes per day, on average Patients who are current meditation practitioners Current or previous neurological disease, which may adversely affect swallowing Current use of antipsychotics All subjects must be willing to be monitored for adequacy of nutritional intake during the intervention, as is the current standard of clinical practice Current use of (other N-methyl D-aspartate [NMDA] antagonists) amantadine, ketamine, or dextromethorphan Current engagement in yoga practice >= day per week Current heterosexual or lesbian sexual partner Current/recent (prior months) pregnancy History of or current neurological illness that significantly impacts cognition (e.g. stroke, multiple sclerosis, Parkinson's disease, Alzheimer's disease, head injury, epilepsy, etc) Current use of a statin Diagnosis of cardiovascular disease (CVD) with or without current statin use Treatment with an anticoagulant for more than days for the current blood clot, prior to randomization Current use of a wearable PAM device as defined by use of PAM device in the last months Currently on or more antidepressant or anti-anxiety therapies for mood disturbance of any kind; past use is allowed, just not current use Free of current ethanol (ETOH) or drug abuse Individuals with a current substance use disorder will also be excluded ONCOLOGY NURSE: Planning to leave their current practice setting for other employment in the next months No current chemo or radio-therapy Current or planned use of methoxyflurane, oral contraceptives, isotretinoin, penicillin, or ergot alkaloids No current diagnosed untreated or unresolved oral candidiasis or oral herpes simplex virus (HSV) infection No current use of glutamine or sucralfate powders at the time of registration (no washout required) Current or past treatment with fluocinonide cream for vaginal dryness, itching, or dyspareunia Known current vaginal infection Any current axis I diagnosis Deafness, current meditation practice (> episodes or > hour total, weekly), and current enrollment in a stress reduction program The subject is a current smoker (has smoked within weeks prior to surgery) DONOR: Current use of statin drug Previous or current neurologic disease affecting the lower hemithorax or below Patient has not yet started current course of RT Current skin disease or fungal infection of the feet; Have no current doctor's diagnosis of anal condyloma, hemorrhoids, fissures, or anal cancer Men with human immunodeficiency virus (HIV) and/or prior anal disease will be included given their increased risk for current disease Current use of thienopyridine therapy (clopidogrel, prasugrel, or ticagrelor) that will be continued on study current known Methicillin-resistant Staphylococcus Aureus (MRSA) colonization; current known Vancomycin Resistant Enterococcus (VRE) colonization; current known immunologically-deficient disease conditions (not including recent chemotherapy); Current treatment with tamoxifen or aromatase inhibitors Current diagnosis or history of cardiac pre-excitation syndromes (e.g. Wolff-Parkinson-White) Current or ex-smoker with at least pack-year history Current participation in another cancer chemoprevention study Current smoker (i.e., at least cigarettes/day) Subjects who have not received the seasonal influenza vaccine in the current flu season and are not suspected to have had an influenza infection in the current flu season Subjects who had or are suspected to have had an influenza infection in the current influenza season Endorse current psychosis. Current use of a retinol containing agent or any retinoid analogue drug within the last days Current sexually transmitted infection (STI) requiring treatment (women may participate after adequate treatment, at the discretion of the treating provider) Current use of statin medication or statin use within months of screen visit Current smoker Prior history or current use of tamoxifen or anti-estrogen therapy Current or prior advanced adenomas Any history of current or prior rectal cancer Current use of statin therapy Current use of rifampin and digoxin Current smoker Treatment with intravesical BCG or chemotherapy for a patients current < T tumor during the months prior to the current diagnosis Any other current or previous malignancy Current use of anti-coagulants Current narcotic use Current or ex-smoker with at least a -year pack history Current use of >= cigarettes/day Current use of >= alcoholic drinks/day Current or history of anal or peri-anal carcinoma Must be a former or current smoker current smoker Current treatment with the anticonvulsant depakote (at time of enrollment) Severe/uncontrolled inter current illness within the previous days prior to PET scan Malignancy other than current disease under study Current use of gabapentin or venlafaxine for hot flashes Any patient with a current case of cellulitis Ileostomy or hepatic resection during current cytoreductive surgery Patients who have already started treatment for the current malignancy Previous inclusion in the current study Patient undergoing current or recent treatment within past weeks or scheduled for any treatment that could results in changes of lesion appearance between the two study examinations. This would include, but not restricted to, the following: current or recent radiation therapy, surgery, starting or recent chemotherapy. Current use of aromatase inhibitor as prevention or treatment for breast cancer Current or recent use of reproductive hormone therapy, tamoxifen, aromatase inhibitor or other estrogen inhibitors within the last days, which may affect biomarkers Current ingestion of broccoli sprout extract, which may confound study results Current or recent treatment for any malignancy within the last one year, which may affect biomarkers Current diagnosis of gastroesophageal reflux disease (GERD) with grade >= History of current oropharyngeal dysphagia unrelated to cancer diagnosis (e.g. dysphagia due to underlying neurogenic disorder) (Arm only) Current smoker, or former smoker who has less than a -year quit history current smoker of at least cigarettes per day for at least year Subjects with a known current condition of substance addiction.